Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member, please register here.

If you are a Medicare Advantage or Medicare Supplement member, please register here.

New Options for Affordable Health Insurance

 

MP 8.01.26 Hematopoietic Stem-cell Transplantation for Acute Myeloid Leukemia  

Medical Policy    
Section
Therapy 
Original Policy Date
12/1/99
Last Review Status/Date
Reviewed with literature search/8:2014
Issue
8:2014
  Return to Medical Policy Index

Disclaimer

Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract.  Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage.  Medical technology is constantly changing, and we reserve the right to review and update our policies periodically. 


Description

Hematopoietic Stem-Cell Transplantation

Hematopoietic stem cells may be obtained from the transplant recipient (autologous HSCT) or from a donor (allogeneic HSCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naïve” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in greater detail in policy No. 7.01.50.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HSCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allogeneic HSCT. Compatibility is established by typing human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA A, B, and DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci.

Conventional Preparative Conditioning for HSCT

The conventional (“classical”) practice of allogeneic HSCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that develops after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse effects that include pre-engraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allogeneic HSCT, immune suppressant drugs are required to minimize graft rejection and GVHD, which also increases the patient’s susceptibility to opportunistic infections.

The success of autologous HSCT is predicated on the ability of cytotoxic chemotherapy with or without radiation to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient prior to undergoing bone marrow ablation. As a consequence, autologous HSCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HSCT are susceptible to chemotherapy-related toxicities and opportunistic infections prior to engraftment, but not GVHD.

Reduced-Intensity Conditioning for Allogeneic HSCT

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is to reduce disease burden but also to minimize as much as possible associated treatment-related morbidity and non-relapse mortality (NRM) in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of NRM and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allogeneic HSCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For the purposes of this policy, the term “reduced-intensity conditioning” will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

AMLAML (also called ANLL) refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. AML is characterized by proliferation of myeloblasts, coupled with low production of mature red blood cells, platelets, and often nonlymphocytic white blood cells (granulocytes, monocytes). Clinical signs and symptoms are associated with neutropenia, thrombocytopenia, and anemia. The incidence of
AML increases with age, with a median of 67 years. Approximately 13,000 new cases are diagnosed annually.

The pathogenesis of AML is unclear. It can be subdivided according to resemblance to different subtypes of normal myeloid precursors using the FAB classification. This system classifies leukemias from M0–M7, based on morphology and cytochemical staining, with immunophenotypic data in some instances. The World Health Organization (WHO) subsequently incorporated clinical, immunophenotypic, and a wide variety of cytogenetic abnormalities that occur in 50% to 60% of AML cases into a classification system that can be used to guide treatment according to prognostic risk categories (see Policy Guidelines section).

The WHO system recognizes 5 major subcategories of AML: (1) AML with recurrent genetic abnormalities; (2) AML with multilineage dysplasia; (3) therapy-related AML and myelodysplasia; (4) AML not otherwise categorized; and (5) acute leukemia of ambiguous lineage. AML with recurrent genetic abnormalities includes AML with t(8;21)(q22;q22), inv(16)(p13:q22) or t(16;16)(p13;q22), t(15;17)(q22;q12), or translocations or structural abnormalities involving 11q23. Younger patients may exhibit t(8;21) and inv(16) or t(16;16). AML patients with 11q23 translocations include 2 subgroups: AML in infants and therapy-related leukemia. Multilineage dysplasia AML must exhibit dysplasia in 50% or more of the cells of 2 lineages or more. It is associated with cytogenetic findings that include -7/del(7q), - 5/del(5q), +8, +9, +11, del(11q), del(12p), -18, +19, del(20q)+21, and other translocations. AML not otherwise categorized includes disease that does not fulfill criteria for the other groups and essentially reflects the morphologic and cytochemical features and maturation level criteria used in the FAB classification, except for the definition of AML as having a minimum of 20% (as opposed to 30%) blasts in the marrow. AML of ambiguous lineage is diagnosed when blasts lack sufficient lineage-specific antigen expression to classify as myeloid or lymphoid.

Molecular studies have identified a number of genetic abnormalities that also can be used to guide prognosis and management of AML. Cytogenetically normal AML (CN-AML) is the largest defined subgroup of AML, comprising approximately 45% of all AML cases. Despite the absence of cytogenetic abnormalities, these cases often have genetic mutations that affect outcomes, 6 of which have been identified. The FLT3 gene that encodes FMS-like receptor tyrosine kinase (TK) 3, a growth factor active in hematopoiesis, is mutated in 33% to 49% of CN-AML cases; among those, 28% to 33% consist of internal tandem duplications (ITD), 5% to 14% are missense mutations in exon 20 of the TK activation loop, and the rest are point mutations in the juxtamembrane domain. All FLT3 mutations result in a constitutively activated protein and confer a poor prognosis. Several pharmaceutic agents that inhibit the FLT3 TK are under investigation.

Complete remissions can be achieved initially using combination chemotherapy in up to 80% of AML patients. However, the high incidence of relapse has prompted research into a variety of postremission strategies using either allogeneic or autologous HSCT.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) (also called acute nonlymphocytic leukemia [ANLL]) refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. AML is characterized by proliferation of myeloblasts, coupled with low production of mature red blood cells, platelets, and often non-lymphocytic white blood cells (granulocytes, monocytes). Clinical signs and symptoms are associated with neutropenia, thrombocytopenia, and anemia. The incidence of AML increases with age, with a median of 67 years. Approximately 13,000 new cases are diagnosed annually.

The pathogenesis of AML is unclear. It can be subdivided according to resemblance to different subtypes of normal myeloid precursors using the French-American-British (FAB) classification. This system classifies leukemias from M0–M7, based on morphology and cytochemical staining, with immunophenotypic data in some instances. The World Health Organization (WHO) subsequently incorporated clinical, immunophenotypic, and a wide variety of cytogenetic abnormalities that occur in 50% to 60% of AML cases into a classification system that can be used to guide treatment according to prognostic risk categories (see Policy Guidelines).

The WHO system recognizes 5 major subcategories of AML: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) therapy-related AML and myelodysplasia (MDS); 4) AML not otherwise categorized; and 5) acute leukemia of ambiguous lineage. AML with recurrent genetic abnormalities includes AML with t(8;21)(q22;q22), inv(16)(p13:q22) or t(16;16)(p13;q22), t(15;17)(q22;q12), or translocations or structural abnormalities involving 11q23. Younger patients may exhibit t(8;21) and inv(16) or t(16;16). AML patients with 11q23 translocations include 2 subgroups: AML in infants and therapy-related leukemia. Multilineage dysplasia AML must exhibit dysplasia in 50% or more of the cells of 2 lineages or more. It is associated with cytogenetic findings that include -7/del(7q), -5/del(5q), +8, +9, +11, del(11q), del(12p), -18, +19, del(20q)+21, and other translocations. AML not otherwise categorized includes disease that does not fulfill criteria for the other groups and essentially reflects the morphologic and cytochemical features and maturation level criteria used in the FAB classification, except for the definition of AML as having a minimum of 20% (as opposed to 30%) blasts in the marrow. AML of ambiguous lineage is diagnosed when blasts lack sufficient lineage-specific antigen expression to classify as myeloid or lymphoid.

Molecular studies have identified a number of genetic abnormalities that also can be used to guide prognosis and management of AML. Cytogenetically normal AML (CN-AML) is the largest defined subgroup of AML, comprising approximately 45% of all AML cases. Despite the absence of cytogenetic abnormalities, these cases often have genetic mutations that affect outcomes, 6 of which have been identified. The FLT3 gene that encodes FMS-like receptor tyrosine kinase (TK) 3, a growth factor active in hematopoiesis, is mutated in 33–49% of CN-AML cases; among those, 28–33% consist of internal tandem duplications (ITD), 5–14% are missense mutations in exon 20 of the TK activation loop, and the rest are point mutations in the juxtamembrane domain. All FLT3 mutations result in a constitutively activated protein and confer a poor prognosis. Several pharmaceutical agents that inhibit the FLT3 TK are under investigation.

Complete remissions can be achieved initially using combination chemotherapy in up to 80% of AML patients. However, the high incidence of relapse has prompted research into a variety of post-remission strategies using either allogeneic or autologous HSCT.


Policy

Allogeneic hematopoietic stem-cell transplantation (HSCT) using a myeloablative conditioning regimen may be considered medically necessary to treat:

  • poor- to intermediate-risk AML in remission (see Policy Guidelines for information on risk stratification), or
  • AML that is refractory to, or relapses following, standard induction chemotherapy, or
  • AML in patients who have relapsed following a prior autologous HSCT and are medically able to tolerate the procedure.

Allogeneic HSCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in patients who are in complete marrow and extramedullary remission, and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen (see Policy Guidelines).

Autologous HSCT may be considered medically necessary to treat AML in first or second remission or relapsed AML if responsive to intensified induction chemotherapy.


Policy Guidelines 

Primary refractory acute myeloid leukemia (AML) is defined as leukemia that does not achieve a complete remission after conventionally dosed (non-marrow ablative) chemotherapy.

In the French-American-British (FAB) criteria, the classification of AML is solely based on morphology as determined by the degree of differentiation along different cell lines and the extent of cell maturation.

Clinical features that predict poor outcomes of AML therapy include, but are not limited to, the following:

  • Treatment-related AML (secondary to prior chemotherapy and/or radiotherapy for another malignancy)
  • AML with antecedent hematologic disease (e.g., myelodysplasia)
  • Presence of circulating blasts at the time of diagnosis
  • Difficulty in obtaining first complete remission with standard chemotherapy
  • Leukemias with monocytoid differentiation (FAB classification M4 or M5)

The newer, currently preferred, World Health Organization (WHO) classification of AML incorporates and interrelates morphology, cytogenetics, molecular genetics, and immunologic markers in an attempt to construct a classification that is universally applicable and prognostically valid. The WHO system was adapted by the National Comprehensive Cancer Network (NCCN) to estimate individual patient prognosis to guide management, as shown in the following table:

Risk Status of AML Based on Cytogenetic and Molecular Factors

Risk Status

Cytogenetic Factors

Molecular Abnormalities

Better

Inv(16), t(8;21), t(16;16)

Normal cytogenetics with isolated NPM1 mutation

Intermediate

Normal

+8 only, t(9;11) only

Other abnormalities not listed with better-risk and poor-risk cytogenetics

c-KIT mutation in patients with t(8;21) or inv(16)

Poor

Complex (3 or more abnormalities)

-5, -7, 5q-, 7q-, +8, Inv3, t(3;3), t(6;9), t(9;22)

Abnormalities of 11q23, excluding t(9;11)

Normal cytogenetics with isolated FLT3-ITD mutations

 

The relative importance of cytogenetic and molecular abnormalities in determining prognosis and guiding therapy is under investigation.

Some patients for whom a conventional myeloablative allotransplant could be curative may be considered candidates for reduced-intensity conditioning (RIC), or non-myeloablative conditioning allogeneic HSCT. It is important to recognize that the myeloablative intensity of different conditioning regimens varies substantially and that the distinction between myeloablative regimens and RIC regimens has not been defined. (1) In this setting, patient selection is critical, and variations exist in the criteria used by transplant centers in the United States and worldwide. In general, candidates for RIC or non-myeloablative conditioning regimen allogeneic HSCT include patients whose age (typically older than 60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status) preclude use of a standard myeloablative conditioning regimen. A patient whose disease relapses following a conventional myeloablative allogeneic HSCT could undergo a second myeloablative procedure if a suitable donor is available and the patient’s medical status would permit it. However, this type of patient would likely undergo RIC prior to a second allogeneic HSCT if a complete remission could be re-induced with chemotherapy.

Autologous HSCT is used for consolidation treatment of intermediate- to poor-risk disease in complete remission, among patients for whom a suitable donor is not available. Better-risk AML often responds well to chemotherapy with prolonged remission if not cure.

The ideal allogeneic donors are HLA-identical siblings, matched at the HLA-A, -B, and DR loci (6 of 6). Related donors mismatched at one locus are also considered suitable donors. A matched, unrelated donor identified through the National Marrow Donor Registry is typically the next option considered. Recently, there has been interest in haploidentical donors, typically a parent or a child of the patient, for which there usually is sharing of only 3 of the 6 major histocompatibility antigens. The majority of patients will have such a donor; however, the risk of GVHD and overall morbidity of the procedure may be severe, and experience with these donors is not as extensive as that with matched donors.

In 2003, CPT centralized codes describing allogeneic and autologous hematopoietic stem-cell support services to the hematology section (CPT 38204-38242). Not all codes are applicable for each stem-cell support procedure. For example, Plans should determine if cryopreservation is performed. A range of codes describe services associated with cryopreservation, storage, and thawing of cells (38208-38215).

CPT 38208 and 38209 describe thawing and washing of cryopreserved cells

CPT 38210-38214 describe certain cell types being depleted

CPT 38215 describes plasma cell concentration


Benefit Application
BlueCard/National Account Issues 

For indications considered investigational, the following considerations may supersede this policy:

  • State mandates requiring coverage for autologous SCT offered as part of NIH-approved clinical trials of autologous bone marrow transplantation.
  • Some plans may participate in voluntary programs offering coverage for patients participating in NIH-approved clinical trials of cancer chemotherapies, including autologous SCT.
  • Some contracts or certificates of coverage (e.g., FEP) may include specific conditions in which autologous SCT would be considered eligible for coverage. 

Rationale

This policy was originally created in 1999 and has been regularly updated with searches of the MEDLINE database. The most recent MEDLINE search was performed through June 18, 2014. 

Hematopoietic stem-cell transplantation (HSCT) has been investigated as consolidation therapy for patients whose disease enters complete remission following initial induction treatment or as salvage therapy in patients who experience disease relapse or have disease that is refractory to induction chemotherapy.

Consolidation Therapy in Remission

Allogeneic HSCT

A meta-analysis of allogeneic HSCT in patients with acute myeloid leukemia (AML) in first complete remission (CR1) pooled data from 5 studies that included a total of 3100 patients.3 Among those patients, 1151 received allogeneic HSCT and 1949 were given alternative therapies including chemotherapy and autologous HSCT. All of the studies employed natural randomization based on donor availability, and an intention-to-treat analysis, with overall survival (OS) and disease-free survival (DFS) as outcomes of interest. This analysis showed a significant advantage of allogeneic HSCT in terms of OS for the entire cohort (fixed-effects model hazard ratio [HR], 1.17; 95% confidence interval [CI], 1.06 to 1.30; p=0.003; random-effects model HR=1.15, 95% C, 1.01 to 1.32; p=0.037) even though none of the individual studies did so. Meta-regression analysis showed that the effect of allogeneic HSCT on OS differed depending on the cytogenetic risk groups of patients, suggesting significant benefit for poor-risk patients (HR=1.39, 95% CI not reported), indeterminate benefit for intermediate-risk cases, and no benefit in better-risk patients compared with alternative approaches. The authors caution that the compiled studies used different definitions of risk categories (eg, SWOG, MRC, EORTC/GIMEMA), but examination shows
cytogenetic categories in those definitions are very similar to the recent guidelines from the National Comprehensive Cancer Network (NCCN) outlined in the Policy Guidelines section.4 Furthermore, the statistical power of the meta-regression analysis is limited by small numbers of cases. However, the results of this meta-analysis are supported in general by data compiled in other reviews.(5-8)

Evidence from the meta-analysis cited here suggests patients with cytogenetically defined better- prognosis disease may not realize a significant survival benefit with allogeneic HSCT in CR1 that outweighs the risk of associated morbidity and nonrelapse mortality (NRM). However, there is considerable genotypic heterogeneity within the 3 World Health Organization (WHO) cytogenetic prognostic groups that complicates generalization of clinical results based only on cytogenetics.9 For example, patients with better-prognosis disease (eg, core-binding factor AML) based on cytogenetics, and a mutation in the c-kit gene of leukemic blast cells, do just as poorly with postremission standard chemotherapy as patients with cytogenetically poor-risk AML.10 Similarly, patients with cytogenetically normal AML (intermediate-prognosis disease) can be subcategorized into groups with better or worse prognosis based on the mutational status of the nucleophosmin gene (NPM1) and the FLT3 gene
(defined earlier in the policy Description). Thus, patients with mutations in NPM1 but without FLT3-ITD (internal tandem duplications) have postremission outcomes with standard chemotherapy that are similar to those with better-prognosis cytogenetics; in contrast, patients with any other combination of mutations in those genes have outcomes similar to those with poor-prognosis cytogenetics.11 These examples highlight the rapidly growing body of evidence for genetic mutations as additional predictors of prognosis and differential disease response to different treatments. It follows that because the earlier clinical trials compiled in the meta-analysis described here did not account for genotypic differences that affect prognosis and alter outcomes, it is difficult to use the primary trial results to draw conclusions concerning
the role of allogeneic HSCT in different patient risk groups.

A second meta-analysis has been published that incorporated data from 24 trials involving a total of 6007 patients who underwent allogeneic HSCT in first complete remission [CR1].(12) Among the total, 3638 patients were stratified and analyzed according to cytogenetic risk (547 good-, 2499 intermediate-, 592 poor-risk AML, respectively) using a fixed-effects model. Compared with either autologous HSCT or additional consolidation chemotherapy, the HR for OS among poor-risk patients across 14 trials was 0.73 (95% CI, 0.59 to 0.90; p<0.01); among intermediate-risk patients across 14 trials, the HR for OS was 0.83 (95% CI, 0.74 to 0.93; p<0.01); among good-risk patients across 16 trials, the HR for OS was 1.07 (95% CI, 0.83 to 1.38; p=0.59). Interstudy heterogeneity was not significant in any of these analyses. Results for DFS were very similar to those for OS in this analysis. These results concur with those from the previously cited meta-analysis3 and the current Policy Statements for use of allogeneic HSCT as consolidation therapy for AML.

A recent study compared the outcome of 185 matched pairs of patients from a large multicenter clinical trial (AMLCG99).13 Patients younger than 60 years who underwent allogeneic HSCT in CR1 were matched to patients who received conventional postremission chemotherapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time inCR1. In the overall pairwise-compared AML population, the projected 7-year OS rate was 58% for the allogeneic HSCT and 46% for the conventional postremission treatment group (log-rank test, p=0.037). Relapse-free survival was 52% in the allogeneic HSCT group compared with 33% in the control group (p<0.001). OS was significantly better for allogeneic HSCT in patient subgroups with nonfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, postremission therapy was an independent factor for OS (HR=0.66; 95% CI, 0.49 to 0.89 for allogeneic HSCT versus conventional chemotherapy), among age, cytogenetics, and bone marrow blasts after the first induction cycle.

Autologous HSCT
A meta-analysis published in 2004 examined survival outcomes of autologous HSCT in CR1 versus standard chemotherapy or no further treatment in AML patients aged 15 to 55 years.(14) Two types of studies were eligible: (1) prospective cohort studies in which patients with an available sibling donor were offered allogeneic HSCT (biologic randomization) with random assignment of all others to autologous HSCT or chemotherapy (or no further treatment); and (2) randomized trials that compared autologous HSCT with chemotherapy in all patients. Among a total of 4058 patients included in 6 studies, 2989 (74%) achieved CR1; 1044 (26%) were randomly allocated to HSCT (n=524) or chemotherapy (n=520). Of the 5 studies for which OS data were available, outcomes with autologous HSCT were better in 3, and outcomes with chemotherapy were better in 2. None of the differences reached statistical significance, nor did the pooled estimate reach statistical significance (fixed-effects model survival probability ratio, 1.01; 95% CI, 0.89 to 1.15; p=0.86). In all 6 studies, DFS was numerically superior with autologous HSCT compared with chemotherapy (or no further treatment), but only 1 reported a statistically significant DFS probability associated with autologous HSCT. However, the pooled estimate for DFS showed a statistically significant probability in favor of autologous HSCT at 48 months post-transplant (fixed-effects model survival probability ratio, 1.24; 95% CI, 1.06 to 1.44; p=0.006).

There are several possible reasons this meta-analysis did not demonstrate a statistically significant OS advantage for autologous HSCT compared with chemotherapy given the significant estimate for DFS benefit. First, the pooled data showed a 6.45% greater NRM rate in autologous HSCT recipients compared with chemotherapy recipients. Second, 14% of chemotherapy recipients whose disease relapsed ultimately achieved a sustained second remission after undergoing an allogeneic or autologous HSCT. The intention-to-treat analysis in the studies, which included the latter cases in the chemotherapy group, may have inappropriately inflated OS rates favoring chemotherapy. Furthermore, this analysis did not take into account potential effects of cytogenetic or molecular genetic differences among patients that
are known to affect response to treatment. Finally, the dataset comprised studies performed between 1984 and 1995, during which transplant protocols and patient management evolved significantly, particularly compared with current care.

A second meta-analysis published in 2010 evaluated autologous HSCT versus further chemotherapy or no further treatment for AML in CR1.15 A total of 9 randomized trials involving 1104 adults who underwent autologous HSCT and 1118 who received additional chemotherapy or no additional treatment were identified. The analyses suggest that autologous HSCT in CR1 was associated with statistically significant reduction of relapse risk (RR=0.56; 95% CI, 0.44 to 0.71; p=0.001) and significant improvement in DFS (HR=0.89; 95% CI, 0.80 to 0.98), but at the cost of significantly increased NRM (RR=1.90; 95% CI, 0.72 to 0.87; p=0.001). There were more deaths during the first remission among patients assigned to autologous HSCT than among the chemotherapy recipients or further untreated patients. As a consequence of increased NRM, no statistical difference in OS (HR=1.05; 95% CI, 0.91 to 1.21) was associated with the use of autologous HSCT, compared with further chemotherapy or no further therapy. These results were concordant with those of the earlier meta-analysis cited earlier.

A prospective, randomized Phase III trial compared autologous HSCT with intensive consolidation chemotherapy among patients (range, 16-60 years old) with newly diagnosed AML of similar risk profiles in complete remission (CR1).(16) Patients in CR1 after 2 cycles of intensive chemotherapy (etoposide and mitoxantrone), who were not candidates for allogeneic HSCT, were randomly allocated between a third consolidation cycle of the same chemotherapy (n=259) or autologous HSCT (n=258). The HSCT group showed a trend toward superior relapse-free survival, the primary outcome, compared with chemotherapy recipients (38% vs 29%, respectively at 5 years, p=0.065; 95% CI, 0.66 to 1.1). HSCT patients had a lower relapse rate at 5 years compared with chemotherapy recipients (58% vs 70%, respectively, p=0.02). Overall survival did not differ between HSCT and chemotherapy recipients, respectively (44% vs 41%, p=0.86). NRM was more frequent in the autologous HSCT group than in the chemotherapy consolidation group (4% vs 1%, respectively, p=0.02). Despite this difference in NRM, the relative equality of OS rates was attributed by the investigators to a higher proportion of successful salvage treatments–second-line chemotherapy, autologous or allogeneic HSCT–in the chemotherapy consolidation recipients that were not available to the autologous HSCT patients. This large study shows an advantage for postremission autologous HSCT in reducing relapse, but similar OS rates secondary to better salvage of chemotherapy-consolidated patients.

The body of evidence summarized in the 2 meta-analyses and randomized controlled trial (RCT) referenced earlier suggests autologous HSCT to treat AML in CR1 is feasible and potentially offers improved DFS, compared with postremission chemotherapy in patients who lack a suitable stem-cell donor. However, this procedure is not considered as first-line postremission therapy for AML patients who are candidates for allogeneic HSCT and for whom a suitable matched donor is available.

Primary Refractory AML
Conventional-dose induction chemotherapy will not produce remission in 20% to 40% of patients with AML, connoting refractory AML.4 An allogeneic HSCT using a matched related donor (MRD) or matched unrelated donor (MUD) represents the only potentially curative option for these patients. In several retrospective studies, OS rates have ranged from 13% at 5 years to 30% at 3 years, although this procedure is accompanied by NRM rates of 25% to 62% in this setting.5 For patients who lack a suitable donor (MRD or MUD), alternative treatments include salvage chemotherapy with high-dose cytarabine or etoposide-based regimens, monoclonal antibodies (eg, gemtuzumab ozogamicin), multidrug resistance modulators, and other investigational agents such as FLT3 antagonists.17 Because it is likely that stem-cell preparations will be contaminated with malignant cells in patients whose disease is not in remission, autologous HSCT has no role in patients who fail induction therapy.(18)

Relapsed AML
Most patients with AML will experience disease relapse after attaining a CR1.(4) Conventional chemotherapy is not curative in most patients following disease relapse, even if a second complete remission (CR2) can be achieved. Retrospective data compiled from 667 of 1540 patients entered in 3 phase III trials suggest allogeneic HSCT in CR2 can produce 5-year OS rates of 26% to 88%, depending on cytogenetic risk stratification.(19) Because reinduction chemotherapy treatment may be associated with
substantial morbidity and mortality, patients whose disease has relapsed and who have a suitable donor may proceed directly to allogeneic HSCT.

In patients without an allogeneic donor, or those who are not candidates for allogeneic HSCT due to age or other factors, autologous HSCT may achieve prolonged DFS in 9% to 55% of patients in CR2 depending on risk category.18,20 However, because it is likely that stem-cell preparations will be contaminated with malignant cells in patients whose disease is not in remission, and it is often difficult to achieve CR2 in these patients, autologous HSCT in this setting is usually limited to patients who have a sufficient stem-cell preparation remaining from collection in CR1.(18)

Allogeneic HSCT is often performed as salvage for patients who have relapsed after conventional chemotherapy or autologous HSCT.18 The decision to attempt reinduction or proceed directly to allogeneic HSCT is based on the availability of a suitable stem-cell donor and the likelihood of achieving a remission, the latter being a function of cytogenetic risk group, duration of CR1 and the patient’s health status. Registry data show DFS rates of 44% using sibling allografts and 30% with MUD allografts at 5 years for patients transplanted in CR2, and DFS of 35% to 40% using sibling transplants and 10% with MUD transplants for patients with induction failure or in relapse following HSCT.(18)

Reduced-Intensity Allogeneic HSCT
A growing body of evidence is accruing from clinical studies of RIC with allogeneic HSCT for AML.(2,21-32) Overall, these data suggest that long-term remissions (2-4 years) can be achieved in patients with AML who, because of age or underlying comorbidities would not be candidates for myeloablative conditioning regimens.

A randomized comparative trial in matched patient groups compared the net health benefit of allogeneic HSCT with reduced-intensity conditioning (RIC) versus myeloablative conditioning. (33-35) In this study, patients (age, 18-60 years) were randomly assigned to receive either RIC (n=99) of 4 doses of 2 Gy of total body irradiation and 150 mg/m² fludarabine or standard conditioning (n=96) of 6 doses of 2 Gy of total body irradiation and 120 mg/kg cyclophosphamide. All patients received cyclosporin and methotrexate as prophylaxis against GVHD. The primary end point was the incidence of NRM analyzed in the intention-to-treat population. This unblinded trial was stopped early because of slow accrual of patients. The incidence of NRM did not differ between the RIC and standard conditioning groups
(cumulative incidence at 3 years, 13% [95% CI, 6 to 21] vs 18% [10 to 26]; HR=0.62 [95% CI, 0.30 to 1.31], respectively). Relapse cumulative incidence at 3 years was 28% (95% CI, 19 to 38) in the RIC group and 26% (17 to 36; HR=1.10 [95% CI, 0.63 to 1.90]) in the standard conditioning group. DFS at 3 years was 58% (95% CI, 49 to 70) in the RIC group and 56% (46 to 67; HR=0.85 [95% CI, 0.55 to 1.32]) in the standard conditioning group. OS at 3 years was 61% (95% CI, 50 to 74) and 58% (47 to 70); HR was 0.77 (95% CI, 0.48 to 1.25) in the RIC and standard conditioning groups, respectively. No outcomes differed significantly between groups. Grade 3 to 4 of oral mucositis was less common in the RIC group than in the standard conditioning group (50 patients in the RIC group vs 73 patients in the standard conditioning group); the frequency of other adverse effects such as GVHD and increased concentrations of bilirubin and creatinine did not differ significantly between groups.

In a recent study, outcomes were compared in children with AML who underwent allogeneic HSCT using RIC regimens or myeloablative conditioning regimens.(36) A total of 180 patients were evaluated, 39 who underwent RIC and 141 who received myeloablative regimens. Univariate and multivariate analyses showed no significant differences in the rates of acute and chronic GVHD, leukemia-free survival, and OS between treatment groups. The 5-year probabilities of OS with RIC and myeloablative regimens were 45% and 48%, respectively (p=0.99). Moreover, relapse rates were not higher with RIC compared with myeloablative conditioning (MAC) regimens (39% vs 39%; p=0.95), and recipients of MAC regimens were not at higher risk for transplant-related mortality compared with recipients of RIC regimens (16% vs 16%; p=0.73).

A phase 2 single-center, randomized toxicity study compared MAC and RIC in allogeneic HSCT to treat AML.(37) Adult patients 60 years of age or younger with AML were randomly assigned (1:1) to treatment with RIC (n=18) or MAC (n=19) for allogeneic HSCT. A maximum median mucositis grade of 1 was observed in the RIC group compared with 4 in the MAC group (p<0.001). Hemorrhagic cystitis occurred in 8 (42%) of the patients in the MAC group and none (0%) in the RIC group (p<0.01). Results of renal and hepatic tests did not differ significantly between the 2 groups. RIC-treated patients had faster platelet engraftment (p<0.01) and required fewer erythrocyte and platelet transfusions (p<0.001) and less total parenteral nutrition than those treated with MAC (p<0.01). Cytomegalovirus infection was more common in the MAC group (14/19) than in the RIC group (6/18) (p=0.02). Donor chimerism was similar in the 2 groups with regard to CD19 and CD33, but was delayed for CD3 in the RIC group. Five-year treatment-related morbidity was approximately 11% in both groups, and rates of relapse and survival were not significantly different. Patients in the MAC group with intermediate cytogenetic AML had a 3-year survival of 73%, compared with 90% among those in the RIC group.

Indirect comparison of nonrandomized or otherwise comparative study results is compromised by heterogeneity among patients, treatments, outcome measures, and insufficient follow-up. Further, RIC with allogeneic HSCT has not been directly compared with conventional chemotherapy alone, which has been the standard of care in patients with AML for whom myeloablative chemotherapy and allogeneic HSCT are contraindicated.

Allogeneic HSCT with RIC is one of several therapeutic approaches for which evidence exists to show improved health outcomes in patients who could expect to benefit from an allogeneic HSCT. Thus, based on currently available data and clinical input as noted in the following sections, RIC allogeneic HSCT may be considered medically necessary in patients who demonstrate complete marrow and extramedullary remission, who could be expected to benefit from a myeloablative allogeneic HSCT, and who, for medical reasons, would be unable to tolerate a myeloablative conditioning regimen. Additional data are necessary to determine whether some patients with AML and residual disease may benefit from RIC allogeneic HSCT.

Ongoing and Unpublished Clinical Trials
A search of the NCI PDQ in July 2013 identified 37 active or approved phase III trials in the United States that involve stem-cell support for patients with AML. Trials include allo- and autografting, using various high-dose chemotherapy regimens

Clinical Input Received From Physician Specialty Societies and Academic Medical Centers
In response to requests, input was received from 1 physician specialty society (2 reviewers) and 1 academic medical center while this policy was under review for February 2009. While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted. There was strong consensus among reviewers that RIC allogeneic HSCT was of value in patients who were in complete remission. There was general support for the policy statements.

Summary of Evidence
A substantial body of published evidence supports the use of allogeneic hematopoietic stem-cell transplantation (HSCT) as consolidation treatment for acute myeloid leukemia (AML) patients in first complete remission (CR1) who have intermediate- or high-risk disease and a suitable donor; this procedure is not indicated for patients in CR1 with good-risk AML.

Data also support the use of allogeneic HSCT for patients in second complete remission (CR2) and beyond who are in chemotherapy-induced remission and for whom a donor is available. Allogeneic HSCT is a consolidation option for those with primary refractory or relapsed disease who can be brought into remission once more with intensified chemotherapy and who have a donor. For patients who are in remission but don’t have a suitable donor, evidence supports the use of autologous HSCT in
consolidation; this procedure is not an option for those who are not in remission.

Allogeneic HSCT using reduced-intensity conditioning is supported by evidence for use in patients who otherwise would be candidates for an allogeneic transplant, but who have comorbidities that preclude use of a myeloablative procedure. These conclusions are generally affirmed in a recent systematic review and analysis of published international guidelines and recommendations, including those of the European Group for Blood and Marrow Transplantation, the American Society for Blood and Marrow Transplantation, the British Committee for Standards in Hematology, the National Comprehensive Cancer Network (NCCN), and the specific databases of the National Guideline Clearinghouse and the Guideline International Network database.(1)

Practice Guidelines and Position Statements
The NCCN clinical practice guidelines (v.2.2014) for acute myeloid leukemia are generally consistent with this policy.(38)

U.S. Preventive Services Task Force Recommendations
Hematopoietic stem-cell transplantation is not a preventive service.

Medicare National Coverage
There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

References:

  1. Hubel K, Weingart O, Naumann F, et al. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. Leuk Lymphoma. Mar 2011;52(3):444-457. PMID 21323525
  2. Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. Cancer Control. Oct 2011;18(4):237-245. PMID 21976242
  3. Yanada M, Matsuo K, Emi N, et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. Apr 15 2005;103(8):1652-1658. PMID 15742336
  4. Greer JP FJ, Rodgers GM, et al., ed Acute myeloid leukemia in adults. Philadelphia: Lippincott Williams & Wilkins; 2009. Wintrobe's Clinical Hematology.
  5. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. May 2008;14(5):556-567. PMID 18410898
  6. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. Nov 2006;91(11):1513-1522. PMID 17082009
  7. Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transplant. Mar 2008;41(5):415-423. PMID 18209726
  8. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. May 1 2007;109(9):3658-3666. PMID 17213292
  9. Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2006:169-177. PMID 17124057
  10. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. Aug 20 2006;24(24):3904-3911. PMID 16921041
  11. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. May 1 2008;358(18):1909-1918. PMID 18450602
  12. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. Jun 10 2009;301(22):2349-2361. PMID 19509382
  13. Stelljes M, Krug U, Beelen DW, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol. Feb 1 2014;32(4):288-296.PMID 24366930
  14. Nathan PC, Sung L, Crump M, et al. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst. Jan 7 2004;96(1):38-45. PMID 14709737
  15. Wang J, Ouyang J, Zhou R, et al. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol. 2010;124(2):61-71. PMID 20616541   
  16. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. Dec 1 2011;118(23):6037-6042. PMID 21951683
  17. Estey EH. Treatment of acute myeloid leukemia. Haematologica. Jan 2009;94(1):10-16. PMID 19118375
  18. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004:98-117. PMID 15561679
  19. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. Mar 20 2005;23(9):1969-1978. PMID 15632409
  20. Breems DA, Lowenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol. Oct 2007;44(4):259-266. PMID 17961725
  21. Oliansky DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. Feb 2008;14(2):137-180. PMID 18215777
  22. Blaise D, Vey N, Faucher C, et al. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. Apr 2007;92(4):533-541. PMID 17488664
  23. Huisman C, Meijer E, Petersen EJ, et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant. Feb 2008;14(2):181-186. PMID 18215778
  24. Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol. Nov 2007;19(6):660-666. PMID 17906468
  25. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. Feb 1 2008;26(4):577-584.PMID 18086801
  26. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. J Clin Oncol. May 3 2010. PMID 20439626
  27. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. Apr 10 2010;28(11):1878-1887. PMID 20212255
  28. De Latour RP, Porcher R, Dalle JH, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: The European Group for Blood and Marrow Transplantation experience. Blood. 2013;122(26):4279-4286. PMID
  29. Hamidieh AA, Alimoghaddam K, Jahani M, et al. Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience. J Pediatr Hematol Oncol. Aug 2013;35(6):e239-245. PMID 23042019
  30. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. Jan 20 2010;28(3):405-411. PMID 20008642
  31. Peffault de Latour R, Porcher R, Dalle JH, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. Dec 19 2013;122(26):4279-4286. PMID 24144640
  32. Pemmaraju N, Tanaka MF, Ravandi F, et al. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. Aug 2013;13(4):485-492. PMID 23769669
  33. Bornhauser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. Oct 2012;13(10):1035-1044. PMID 22959335
  34. Scherwath A, Schirmer L, Kruse M, et al. Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology. Jul 2013;22(7):1509-1516. PMID 22945857
  35. Shayegi N, Kramer M, Bornhauser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. Jul 4 2013;122(1):83-92. PMID 23656730
  36. Bitan M, He W, Zhang MJ, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. Mar 6 2014;123(10):1615-1620. PMID 24435046
  37. Ringden O, Erkers T, Aschan J, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. Aug 2013;274(2):153-162. PMID 23432209
  38. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines: Acute myeloid leukemia V2.2014. 2014;
    https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/aml
    .pdf. Accessed June, 2014.

Codes

Number

Description

CPT 

38204 

Management of recipient hematopoietic cell donor search and cell acquisition 

 

38205 

Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogeneic 

 

38206 

Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, autologous 

 

38208 

Thawing of previously frozen harvest 

 

38209 

Washing of harvest 

 

38210 

Specific cell depletion with harvest, T-cell depletion 

 

38211 

Tumor cell depletion 

 

38212 

Red blood cell removal 

 

38213 

Platelet depletion 

 

38214 

Plasma (volume) depletion 

 

38215 

Cell concentration in plasma, mononuclear, or buffy coat layer 

 

38220 

Bone marrow, aspiration only 

 

38221 

Biopsy, needle or trocar 

  38230 Bone marrow harvesting for transplantation

 

38240 

Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic 

 

38241 

Bone marrow or blood-derived peripheral stem-cell transplantation; autologous 

 

38242 

Allogeneic donor lymphocyte infusions 

ICD-9 Procedure 

41.00 Bone marrow transplant, not otherwise specified

 

41.01 

Autologous bone marrow transplant 

 

41.02 

Allogeneic bone marrow transplant with purging 

 

41.03 

Allogeneic bone marrow transplant without purging 

 

41.04 

Autologous hematopoietic stem-cell transplant 

 

41.05 

Allogeneic hematopoietic stem-cell transplant 

  41.07 Autologous hematopoietic stem-cell transplant with purging
  41.08 Allogeneic hematopoietic stem-cell transplant with purging
  41.09 Autologous bone marrow transplant with purging

 

41.91 

Aspiration of bone marrow from donor for transplant 

 

99.79 

Other therapeutic apheresis (includes harvest of stem cells) 

ICD-9 Diagnosis 

205.00–205.01 

Acute myeloid leukemia code range 

HCPCS 

Q0083, Q0084, Q0085 

Chemotherapy administration code range 

 

J9000, J9001, J9010, J9015, J9017, J9020, J9025, J9027, J9031, J9035, J9040, J9041, J9045, J9050, J9055, J9060, J9062, J9065, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097, J9098, J9100, J9110, J9120, J9130, J9140, J9150, J9151, J9160, J9165, J9170, J9175, J9178, J9181, J9182, J9185, J9190, J9200, J9201, J9202, J9206, J9208, J9209, J9211, J9212, J9213, J9214, J9215, J9216, J9217, J9218, J9219, J9225, J9226, J9230, J9245, J9250, J9260, J9261, J9263, J9264, J9265, J9266, J9268, J9270, J9280, J9290, J9291, J9293, J9300, J9303, J9305, J9310, J9320, J9340, J9350, J9355, J9357, J9360, J9370, J9375, J9380, J9395, J9600, J9999 

Chemotherapy drug code range 

 

S2140 

Cord blood harvesting for transplantation, allogeneic 

 

S2142 

Cord blood derived stem-cell transplantation, allogeneic 

 

S2150 

Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic, and emergency services) 

ICD-10-CM (effective 10/1/15) C92.00-C92.02 Acute myeloblastic leukemia code range  
   C92.40-C92.42 Acute promyelocytic leukemia code range  
   C92.50-C92.52 Acute myelomonocytic leukemia code range  
ICD-10-PCS (effective 10/1/15) 30243G0, 30243G1, 30243X0, 30243X1, 30243Y0, 30243Y1 Percutaneous transfusion, central vein, bone marrow or stem cells, autologous or nonautologous, code list 

Type of Service 

Therapy 

Place of Service 

Inpatient/Outpatient 


Index

Bone Marrow Transplant
High-dose Chemotherapy; Acute Myeloid Leukemia
Stem- cell Transplant; Acute Myeloid Leukemia  
 


Policy History

 

Date Action Reason
12/01/99 Add to Therapy section New policy represents revision of original policy No. 8.01.15 to focus entirely on AML; policy statement unchanged
08/18/00 Replace policy Policy statement revised to state that allogeneic transplant after a prior failed autotransplant is considered investigational, based on 2000 TEC Assessment
12/18/02 Replace policy Literature review update conducted in October 2002, references added; no change in policy statement. Updated CPT codes
11/9/04 Replace policy Literature review update conducted in August 2004; policy updated with references, NCCN guidelines, and NCI clinical trials information. Policy statement unchanged
09/27/05 Replace policy Literature review update for the period of August 2004 through August 2005; policy statement unchanged. NCI clinical trials and reference number 9 updated 
06/12/08 Replace policy Policy updated with literature review; terminology in policy statements modified but materially unchanged. NCI clinical trials updated, and reference numbers 12-17 added. “High-dose chemotherapy” removed from title and policy statement. 
2/12/09 Replace policy  Clinical input reviewed; policy statement changed to indicate that, Reduced-intensity conditioning allogeneic SCT may be considered medically necessary as a treatment of AML in patients who are in complete marrow and extramedullary first or second remission, and who for medical reasons, would be unable to tolerate a myeloablative conditioning regimen. 
05/14/09 Replace policy Policy updated with literature review; clinical input reviewed, rationale revised extensively. While all policy statements were revised, the two major changes are indicating that allogeneic HSCT may be used in those with poor- to intermediate-risk AML in remission and that allogeneic HSCT may be used after failed autologous HSCT. New references 1, 3, 5-14 added
6/10/10 Replace policy Policy updated with literature search; references 10, 21–23 added. No change to policy statements
8/11/11 Replace policy Policy updated with literature search; reference 12 added. No change to policy statements
08/09/12 Replace policy Policy updated with literature search; reference 14 added. No change to policy statements
8/08/13 Replace policy Policy updated with literature search through July 1, 2013; reference 27 added. No change to policy statements
8/14/14 Replace policy Policy updated with literature review through June 18, 2014; references 13 and 35-36 added. No change to policy statements